EBITDA swung $12.9m positive but operating cash collapsed 94% to $1.0m

What changed

Total revenue was essentially flat at $44.9m versus $44.8m, but mix shifted: recurring revenue grew 13%, driving EBITDA to a $6.4m profit from a $6.5m loss, a $12.9m swing. The pre-tax loss narrowed to $2.1m from $47.9m (a 95.6% improvement), and NPAT improved to a $2.8m loss from $42.4m. Operating cash flow, however, fell to $1.0m from $16.7m (down 94.0%), and the cash balance contracted to $58.1m from $96.0m. Gross borrowings were cut to $16.5m from $21.3m, so net cash remains positive at $41.6m but is $33.1m lower than the prior comparable. Trade debtors rose 40.3% to $46.3m against flat revenue. No interim dividend was declared.

What matters

• Recurring-revenue leverage is real at the EBITDA line. With group revenue flat, a 13% lift in recurring revenue alone produced a $12.9m EBITDA swing, supporting management's mix-quality narrative.
• Cash conversion has deteriorated sharply. OCF/EBITDA is just 15.6% this half versus a large prior-period distortion, and the $15.7m decline in operating cash flow is the single most important negative in the release. Receivable days stretched from about 134 to 188 on broadly unchanged revenue, pointing to a working-capital drag that largely explains the gap between a recovering P&L and a thinner cash buffer.
• Balance-sheet direction is weakening even without added debt. Cash fell $37.9m year-on-year and equity fell $17.6m to $165.2m. The group is still net-cash, but the runway is narrower heading into a recovery that management describes as ongoing rather than complete.

Expectations

No forward-work figure, revenue target or earnings guidance was disclosed in the supplied excerpts, so the result cannot be benchmarked against a stated plan. Against the FY20 shape, HY21 revenue annualised at $89.8m is only modestly above FY20's $87.5m, so this half does not yet evidence a sharp top-line recovery — the positive read is entirely at the mix and EBITDA lines. FY20 was H1-weighted for losses (HY20 carried roughly 74.8% of the full-year NPAT loss and 57% of the EBITDA loss), which flattered the comparison base; a like improvement in H2 is not automatic from this release.

Quality of result

The P&L recovery is genuine at the operating level — EBITDA and PBT both moved materially on a flat revenue base, and no large non-recurring items were extracted. However, two caveats temper the quality read. First, the tax line shifted adversely: prior HY20 carried a $4.7m tax benefit (effective rate -9.8%), whereas HY21 records a $0.5m charge on a pre-tax loss (23.8%), so PBT (up 95.6%) is the cleaner operating read than NPAT (up 93.4%). Second, and more material, the $15.7m decline in operating cash flow against a $12.9m improvement in EBITDA shows the earnings recovery has not yet translated into cash. The $13.3m build in trade receivables absorbs most of that gap, flagging this half as working-capital-adverse rather than cash-generative. Prior-half capex was $8.1m (18.1% of revenue); current capex was not disclosed, so free cash flow cannot be computed.

Unresolved

• Why did receivable days extend to roughly 188 days, and does this reflect customer-payment stress in the exhibitor base or a timing effect that reverses in H2?
• What is the current-period segment split (Cinema, Movio, AGC), given HY20 segment data is the only split extracted? The mix shift beneath flat group revenue cannot be quantified from the release as supplied.
• What was capex in HY21, and therefore what is underlying free cash flow and the cash-burn trajectory against FY20's disclosed $3–4m per month H2 burn range?
• Is there a quantified ARR or forward-work figure that would validate the 13% recurring-revenue trajectory beyond a single half?

This briefing cannot assess valuation, customer concentration, or current-period segment profitability, as none of those were disclosed in the supplied extraction data.

Key metrics

Segment breakdown

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.